{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(1)"],"submitter":["Khan S"],"funding":["Janssen Vaccines & Prevention, Leiden, Netherlands"],"pubmed_abstract":["The adenovirus (Ad)26 serotype-based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector-based vaccines significantly influences antigen-specific immune responses induced by a subsequent vaccination with Ad26 vector-based vaccine regimens against different disease targets in non-human primates. A homologous Ad26 vector-based vaccination regimen or heterologous regimens (Ad26/Ad35 or Ad26/Modified Vaccinia Ankara [MVA]) induced target pathogen-specific immunity in animals, but also persistent neutralizing antibodies and T-cell responses against the vectors. However, subsequent vaccination (interval, 26-57 weeks) with homologous and"],"journal":["NPJ vaccines"],"pagination":["146"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664441"],"repository":["biostudies-literature"],"pubmed_title":["Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets."],"pmcid":["PMC9664441"],"pubmed_authors":["Serroyen J","Schuitemaker H","Salisch NC","Zahn RC","Boer KF","Boedhoe S","Khan S","Gil AI"],"additional_accession":[]},"is_claimable":false,"name":"Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets.","description":"The adenovirus (Ad)26 serotype-based vector vaccine Ad26.COV2.S has been used in millions of subjects for the prevention of COVID-19, but potentially elicits persistent anti-vector immunity. We investigated if vaccine-elicited immunity to Ad26 vector-based vaccines significantly influences antigen-specific immune responses induced by a subsequent vaccination with Ad26 vector-based vaccine regimens against different disease targets in non-human primates. A homologous Ad26 vector-based vaccination regimen or heterologous regimens (Ad26/Ad35 or Ad26/Modified Vaccinia Ankara [MVA]) induced target pathogen-specific immunity in animals, but also persistent neutralizing antibodies and T-cell responses against the vectors. However, subsequent vaccination (interval, 26-57 weeks) with homologous and","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T15:41:08.789Z","creation":"2024-10-15T07:17:41.539Z"},"accession":"S-EPMC9664441","cross_references":{"pubmed":["36379957"],"doi":["10.1038/s41541-022-00567-w"]}}